High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
作者： Monique Terwijn , Wim L.J. van Putten , Angèle Kelder , Vincent H.J. van der Velden , Rik A. Brooimans
关键词:
摘要: Purpose Half the patients with acute myeloid leukemia (AML) who achieve complete remission (CR), ultimately relapse. Residual treatment-surviving is considered responsible for outgrowth of AML. In many retrospective studies, detection minimal residual disease (MRD) has been shown to enable identification these poor-outcome by showing its independent prognostic impact. Most studies focus on molecular markers or analyze data in retrospect. This study establishes value immunophenotypically assessed MRD context a multicenter clinical trial adult AML sample collection and analysis performed few specialized centers.
ru.nl
vumc.nl
narcis.nl参考文章(27)
J.F. San Miguel, A. Martı́nez, A. Macedo, M.B. Vidriales, C. López-Berges, M. González, D. Caballero, M.A. Garcı́a-Marcos, F. Ramos, J. Fernández-Calvo, M.J. Calmuntia, J. Diaz-Mediavilla, A. Orfao, Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients Blood. ,vol. 90, pp. 2465- 2470 ,(1997) , 10.1182/BLOOD.V90.6.2465
David Grimwade, Helen Walker, Fiona Oliver, Keith Wheatley, Christine Harrison, Georgina Harrison, John Rees, Ian Hann, Richard Stevens, Alan Burnett, Anthony Goldstone, The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial Blood. ,vol. 92, pp. 2322- 2333 ,(1998) , 10.1182/BLOOD.V92.7.2322
Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Gerrit Jan Schuurhuis, Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms British Journal of Haematology. ,vol. 153, pp. 421- 436 ,(2011) , 10.1111/J.1365-2141.2011.08595.X
N Feller, M A van der Pol, A van Stijn, G W D Weijers, A H Westra, B W Evertse, G J Ossenkoppele, G J Schuurhuis, MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia Leukemia. ,vol. 18, pp. 1380- 1390 ,(2004) , 10.1038/SJ.LEU.2403405
Wolfgang Kern, Claudia Haferlach, Torsten Haferlach, Susanne Schnittger, Monitoring of minimal residual disease in acute myeloid leukemia Cancer. ,vol. 112, pp. 4- 16 ,(2008) , 10.1002/CNCR.23128
V H J van der Velden, A van der Sluijs-Geling, B E S Gibson, J G te Marvelde, P G Hoogeveen, W C J Hop, K Wheatley, M B Bierings, G J Schuurhuis, S S N de Graaf, E R van Wering, J J M van Dongen, Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia. ,vol. 24, pp. 1599- 1606 ,(2010) , 10.1038/LEU.2010.153
Anna van Rhenen, Guus A. M. S. van Dongen, Angèle Kelder, Elwin J. Rombouts, Nicole Feller, Bijan Moshaver, Marijke Stigter-van Walsum, Sonja Zweegman, Gert J. Ossenkoppele, Gerrit Jan Schuurhuis, The novel AML stem cell–associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells Blood. ,vol. 110, pp. 2659- 2666 ,(2005) , 10.1182/BLOOD-2007-03-083048
Jason P. Fine, Robert J. Gray, A Proportional Hazards Model for the Subdistribution of a Competing Risk Journal of the American Statistical Association. ,vol. 94, pp. 496- 509 ,(1999) , 10.1080/01621459.1999.10474144
Elaine Coustan-Smith, Raul C. Ribeiro, Jeffrey E. Rubnitz, Bassem I. Razzouk, Ching-Hon Pui, Stanley Pounds, Martin Andreansky, Frederick G. Behm, Susana C. Raimondi, Sheila A. Shurtleff, James R. Downing, Dario Campana, Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. British Journal of Haematology. ,vol. 123, pp. 243- 252 ,(2003) , 10.1046/J.1365-2141.2003.04610.X
Dario Campana, Status of minimal residual disease testing in childhood haematological malignancies. British Journal of Haematology. ,vol. 143, pp. 481- 489 ,(2008) , 10.1111/J.1365-2141.2008.07350.X